Biodesign program wins national award for excellence
By Richard Schoonraad | Molecular Endocrinology and Pharmacology, News & EventsA program that provides industry engagement opportunities and training in biomedical design thinking, while giving industry access to research talent has won a national award. iPREP Biodesign, administered by The…
Phase 3 drug trial for rare chronic kidney disease achieves key milestone
By Richard Schoonraad | Chronic Kidney Disease, Kidney Disease, Lab, Media Releases, Molecular Endocrinology and Pharmacology, News & Events, Research, Research AreaBiopharmaceutical company, Dimerix Limited (ASX: DXB, “Dimerix”), which is developing new treatments for types of inflammatory kidney and respiratory diseases, has announced successful interim results of a Phase 3 trial…
Federal government supports new treatment to clear blocked arteries
By Richard Schoonraad | Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Science and Diabetes Program, Diabetes, Funding, News & Events, ResearchA Western Australian medical research team developing a new treatment for cardiovascular disease has received $2,147,254 in Federal government funding to develop a first-ever drug to clear blocked arteries. The…
AI stethoscope to help detect early signs of heart disease
By Richard Schoonraad | Advanced Clinical and Translational Cardiovascular Imaging, Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Science and Diabetes Program, Heart, News & Events, TreatmentsNew AI stethoscope could revolutionise medicine and help detect the early signs of heart valve disease A digital stethoscope that will easily be able to detect early signs of heart…
Federally funded WA biomedical start-ups
By Richard Schoonraad | Antibiotic diagnostics, Bacteria, Kidneys, News & Events, Targeted Drug DeliveryCutting-edge biopolymer 3D printed heart valve technology and a rapid and accurate test to identify the most effective antibiotic treatment have commenced commercialisation in Western Australia to help millions globally.…
3D Printed heart valves to be commercialised
By Richard Schoonraad | Biomedical engineering, Cardiovascular Disease, Cardiovascular Disease, Heart, Media Releases, News & Events, T3mPLATE Laboratory, Vascular EngineeringCutting-edge biopolymer 3D-printed heart valve technology to be commercialised in Australia to help millions globally suffering from aortic stenosis. CUREator, Australia’s national biotech incubator, funds Western Australian biomedical engineering and…
Antibiotics resistance solution to be commercialised
By Richard Schoonraad | Bacteria, Cardiovascular Science and Diabetes Program, Emergency Medicine, Kidney Disease, Media Releases, News & Events, Synthetic Biology and Drug Discovery, Targeted Drug Delivery, TranslationBreakthrough diagnostic technology to be commercialised in Australia in race to save millions globally from antibiotic resistant sepsis. CUREator funds Western Australian research team to develop life-saving technology through the…

Further mysteries of cardiovascular disease-causing plaque revealed
By Richard Schoonraad | Blood Vessels, Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Science and Diabetes Program, Heart, Media Releases, News & Events, ResearchNew discoveries on where plaque can form and what can trigger a heart attack. Researchers from the Harry Perkins Institute of Medical Research have published new findings that turn the…